According to Granada Salud, an online news outlet in Granada, REGEMAT has begun selling its bioprinting systems and bioreactors to 28 countries. At the beginning of the year, they introduced REG4Life bioprinter and are in the process of raising funds with their target set at 3 million Euros to aid their expansion to the global market.
As a leading player in the bioprinting field, REGEMAT 3D has come up with a novel process for the creation of three-dimensional fabrics. The 3D mould is printed then it’s matured in a bioreactor using several mechanobiological signals that finally produce a functional tissue. This technology allows for the production of cartilage parts for implantation that can be tested in the bioreactor before they are used on a patient.
Under the leadership of Jose Manuel Baena, the company aims at provision of bioprinting systems that are adaptable to various research fields. They also lend their bioreactors (BMAP) for maturing tissues as well as the consumables needed to facilitate this procedure. REGEMAT’s technology is currently available to users in 28 countries globally and includes places like Argentina, Australia, Canada, China, European Union, Mexico, Saudi Arabia, and the USA.
New Bioprinting System by REGEMAT
REGEMAT has not been adversely affected by the pandemic since they are able to produce 3-Dimensional models of tissues attacked by the virus. Their introduction of REG4Life bioprinter in addition to their existing BMAP bioreactor line has seen them have an improved and advanced version. Jose Manuel Baena, a Biomedicine doctor and Founder of REGEMAT 3D says that there is growth in the Bioprinting market and more researchers are now focusing on 3-dimension and tissue maturation while conducting investigations. He adds that with time, these research undertakings will come up with applications that can allow for the production of tissues that have clinical value.
REGEMAT 3D increased its revenues fourfold in the last two years and has a 700,00 Euros financing from ICO funds, CDTI Cervera instrument and H2020 program. They are also looking into equity investors through a crowdfunding program.
The bioprinting business holds a lot of promise for the future with some of its outstanding applications being regenerative medicine, scientific research on diseases, drugs, and cosmetics. It holds the key to reduced reliance on animals for research as well as a means for achieving medical solutions within clinical fields. Particularly it’s driving factor is the very problem it intends to solve; enhancing the quality of life among older populations.